%0 Journal Article
%T Diagnostic performance of multiplex lateral flow tests in ambulatory patients with acute respiratory illness.
%A Murphy C
%A Mak L
%A Cheng SMS
%A Liu GYZ
%A Chun AMC
%A Leung KKY
%A Sum NYW
%A Poukka E
%A Peiris M
%A Cowling BJ
%J Diagn Microbiol Infect Dis
%V 110
%N 1
%D 2024 Sep 4
%M 38972132
%F 2.983
%R 10.1016/j.diagmicrobio.2024.116421
%X We assessed the performance of three different multiplex lateral flow assays manufactured by SureScreen, Microprofit and Goldsite which provide results for influenza, respiratory syncytial virus (RSV) and SARS-CoV-2. Between 4 April and 20 October 2023, 1646 patients 6 months and older presenting to an outpatient department of a hospital in Hong Kong with ≥2 symptoms or signs of an acute respiratory illness were enrolled. The point estimates for all three multiplex tests had sensitivity >80% for influenza A and SARS-CoV-2 compared to PCR, and the tests manufactured by Microprofit and Goldsite had sensitivity >84% to detect RSV. Specificity was >97% for all three tests except for the SureScreen test which had specificity 86.2% (95% CI: 83.9% to 88.3%) for influenza A. Sensitivity was lower than reported by the manufacturers, resulting in a higher risk of false negatives. The three multiplex tests performed better in patients with high viral loads.